eCite Digital Repository

AstraZeneca COVID-19 vaccine and Guillain- Barr acute accent e Syndrome in Tasmania: a causal link?

Citation

Oo, Wai M and Giri, Pradeep and de Souza, Aaron, AstraZeneca COVID-19 vaccine and Guillain- Barr acute accent e Syndrome in Tasmania: a causal link?, Journal of Neuroimmunology, 360 Article 360:577719. ISSN 0165-5728 (2021) [Refereed Article]


Preview
PDF
Pending copyright assessment - Request a copy
6Mb
  

DOI: doi:10.1016/j.jneuroim.2021.577719

Abstract

The emergence of the coronavirus 2019 (COVID-19) pandemic has presented an unprecedented global challenge. Vaccines against COVID have been developed to date. Covid-19 has been linked with the development of Guillain-Barre Syndrome (GBS), a rare immune-mediated demyelinating neuropathy. We report three cases of Guillain-Barre Syndrome and one case of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), presenting to a Tasmanian hospital, and review 15 other reported cases and discuss likely immunopathology. Nearly all reported cases of post-COVID-19 vacciation inflammatory demyelinating polyneuropathy are linked to AstraZeneca vaccination and a variant with bifacial weakness is the most reported form of GBS globally.

Item Details

Item Type:Refereed Article
Keywords:AstraZeneca vaccine, COVID-19, COVID-19 vaccine, Chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre syndrome, Inflammatory demyelinating polyneuropathy
Research Division:Biomedical and Clinical Sciences
Research Group:Immunology
Research Field:Cellular immunology
Objective Division:Health
Objective Group:Clinical health
Objective Field:Prevention of human diseases and conditions
UTAS Author:de Souza, Aaron (Dr Aaron de Souza)
ID Code:152400
Year Published:2021
Web of Science® Times Cited:17
Deposited By:Medicine
Deposited On:2022-08-18
Last Modified:2022-08-18
Downloads:0

Repository Staff Only: item control page